1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 46 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2017CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patientsBarratt, D.; Cox, H.; Menelaou, A.; Yeung, D.; White, D.; Hughes, T.; Somogyi, A.
2010Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?Fitter, S.; Vandyke, K.; Schultz, C.; White, D.; Hughes, T.; Zannettino, A.
2014Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinibEadie, L.; Hughes, T.; White, D.
2013Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2Eadie, L.; Saunders, V.; Hughes, T.; White, D.
2018ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cellsEadie, L.; Dang, P.; Goyne, J.; Hughes, T.; White, D.
2016ABCB1 Overexpression Is a key initiator of resistance to tyrosine kinase inhibitors in CML cell linesEadie, L.; Hughes, T.; White, D.
2016ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatmentEadie, L.; Hughes, T.; White, D.; New Directions in Leukaemia Research 2016 Meeting (NDLR) (16 Mar 2016 - 19 Mar 2016 : Noosa, QLD)
2013Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
2013Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapyAngelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
2017CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressorsHughes, A.; Clarson, J.; Tang, C.; Vidovic, L.; White, D.; Hughes, T.; Yong, A.

Discover